Policy & Regulation
MetaVia announces presentation of DA-1726 Phase 1 data at Precision Liver Symposium
28 October 2026 - Biotechnology company MetaVia Inc (Nasdaq: MTVA) announced on Wednesday that it will present Phase 1 clinical trial data for DA-1726, its investigational dual GLP-1 and glucagon rece...
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
28 October 2026 - Danish biotechnology company Genmab A/S (CPH:GMAB) on Wednesday announced positive topline results from its Phase 3 LiGeR-HN1 trial, showing that petosemtamab combined with pembroliz...
United Therapeutics receives FDA clearance to advance inhaled PAH therapy into clinical trials
28 October 2026 - Biotechnology company United Therapeutics Corporation (Nasdaq:UTHR) announced on Wednesday that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug app...
US WorldMeds acquires Orbus Therapeutics
28 October 2026 - US-based specialty pharmaceutical company US WorldMeds Ventures LLC announced on Tuesday a definitive merger agreement under which it has acquired Orbus Therapeutics Inc, a privately...
DifGen Pharmaceuticals completes European Decentralised Procedure for Tafamidis 61 mg Capsules
28 October 2026 - US-based pharmaceutical company DifGen Pharmaceuticals LLC announced on Tuesday the successful completion of the European Decentralised Procedure (DCP) for Tafamidis 61 mg Capsules, ...
Astellas and Audax Biosciences sign exclusive option and licence agreement for DAX-044
28 October 2026 - Japanese pharmaceutical company Astellas Pharma Inc (TSE:4503) and Australian biotechnology company Audax Biosciences Pty Ltd announced on Tuesday that they have entered into an excl...